Evazarsen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Evazarsen sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Evazarsen sodium overview
IONIS-AGT-LRx is under development for treatment-resistant hypertension, mild hypertension and heart failure with reduced ejection fraction (systolic heart failure). It is administered through the subcutaneous route. It is an antisense oligonucleotide which acts by targeting angiotensinogen (AGT). It is developed based on ligand conjugation antisense (LICA) technology.
Ionis Pharmaceuticals overview
Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in California, the US.
For a complete picture of Evazarsen sodium’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
